Fig. 5
Bcl2/Bcl-XL inhibitors specifically target Olaparib-induced senescent cells. a–d Fold change in cell number (a, c) and percentage of dead cells (b, d) on day-6 of treatment regimens indicated in a, c (right panels). e, f Representative proliferation curves (e) or fold change in cell number (f) of HGSOC H2B-GFP cells treated with Olaparib for 9 days (light green), or for 6 days and sequential addition of ABT-263 for the next 3 days (dark green), or treated with Olaparib for 3 days and then without for the next 6 days (orange), or treated with Olaparib for 3 days and sequential addition of ABT-263 for the next 6 days (red). g, h Heat map of Bliss scores (g) or Senolytic Indexes (h) for combination treatments between Olaparib IC50 concentrations and different concentrations of senolytics (see Supplementary Fig. 6D) for 3 days (0–3 days) or treated with Olaparib for 6 days with sequential addition of inhibitors after 3 days of Olaparib (3–6 days) of HGSOC cells expressing H2B-GFP. Data in (e) are representative curves of at least three independent experiments. For all the data, the mean ± SEM of three independent experiments is shown. Data were analyzed using the two-tail Student t test. * Denotes p < 0.05, **p < 0.01, and ***p < 0.001
